Company: ZVRA
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001628280-25-039967
Chunk: 50

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part I, Item 1
Chunk 50
---
:Purchases of property and equipment(312)— Purchases of investments(157,712)(129)Maturities of investments30,500 14,793 Proceeds from sale of PRV150,000 — Net cash provided by investing activities22,476 14,664 Cash flows from financing activities:Proceeds from issuance of debt, net of lender fees— 58,990 Payment of third-party debt issuance costs— (2,091)Repayment of debt— (42,700)Proceeds from insurance financing arrangements— 1,082 Proceeds from Employee Stock Purchase Plan413 551 Proceeds from issuance of common stock for options exercised2,947 1,146 Payments of principal on insurance financing arrangements(372)(431)Net cash provided by financing activities2,988 16,547 Effect of exchange rate changes on cash and cash equivalents286 274 Net increase (decrease) in cash and cash equivalents13,927 (3,789)Cash and cash equivalents, beginning of period33,785 43,049 Cash and cash equivalents, end of period$47,712 $39,260 Supplemental cash flow information:Cash paid for interest$2,626 $2,135 Right-of-use assets obtained in exchange for lease liabilities1,115 — 

See accompanying notes to unaudited condensed consolidated financial statements.

9

ZEVRA THERAPEUTICS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

A.    Description of Business, Basis of Presentation, and Significant Transactions

OrganizationZevra Therapeutics, Inc. (the “Company” or “Zevra”) is a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases. The Company has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. On September 20, 2024, the U.S. Food and Drug Administration (“FDA”) approved the New Drug Application (“NDA”) for MIPLYFFA® (arimoclomol), an orally-delivered treatment for Niemann-Pick disease type C (“NPC”), which is an ultra-rare and progressive neurodegenerative disease. MIPLYFFA, the first FDA-approved treatment for NPC, is indicated for use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and